Healthcare Industry News: Conor Medsystems
News Release - February 24, 2006
Conor Medsystems Announces Decision from U.K. High Court of JusticeRuling Invalidates Angiotech Patent on Paclitaxel Coated Stents
MENLO PARK, Calif., Feb. 24 (HSMN NewsFeed) -- Conor Medsystems, Inc. (Nasdaq: CONR ) announced that the High Court of Justice in the United Kingdom today handed down its decision in Conor's lawsuit to invalidate EP 0 706 376 to Angiotech Pharmaceuticals, Inc. The patent is exclusively licensed to Boston Scientific Corporation for use in the field of coronary stents. Mr. Justice Pumfrey ruled that Angiotech's patent is invalid for obviousness over three separate prior art references.
About Conor Medsystems
Conor Medsystems, Inc. develops innovative controlled vascular drug delivery technologies, and has initially focused on the development of drug eluting stents to treat coronary artery disease. For further information on Conor Medsystems and controlled vascular delivery, visit www.conormed.com.
Source: Conor Medsystems
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.